Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | QPCT | Q16769 | 2/20 | 0.37 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 4/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2662422 | 0.97 | CNR1 (0.39) | SCN5ASCN9AQPCTASAH1KDM4E | |
| SCHEMBL14380104 | 0.85 | BRD4 (0.42) | CNR2 | |
| SCHEMBL2661076 | 0.83 | KDM4C (0.38) | ASAH1SRC | |
| SCHEMBL5582964 | 0.80 | KDM4C (0.37) | ASAH1CNR1CNR2SRC | |
| SCHEMBL2660965 | 0.79 | SCN9A (0.41) | SCN5ASCN9ATBK1 | |
| SCHEMBL2660425 | 0.77 | CCR2 (0.44) | SCN5ASCN9A | |
| SCHEMBL2660265 | 0.74 | CCR2 (0.43) | SCN5ASCN9A | |
| SCHEMBL11750074 | 0.74 | ASAH1 (0.47) | ASAH1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5583119 | 0.73 | CCR2 (0.39) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14380101 | 0.72 | CNR1 (0.47) | CNR1CNR2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966152-A2 | GLUCOKINASE ACTIVATORS | Takeda Pharmaceutical Company Limited (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-10-18 | — | — | US | disclosed |
| WO-2007075847-A2 | GLUCOKINASE ACTIVATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | SCN5A 2766/4885SCN9A 3230/4885QPCT 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.